Caris Life Sciences Inc’s recently made public that its insider Denton John Russel acquired Company’s shares for reported $0.1 million on Nov 07 ’25. In the deal valued at $24.09 per share,4,184 shares were bought. As a result of this transaction, Denton John Russel now holds 9,184 shares worth roughly $0.23 million.
Then, Spetzler David Baxley bought 400 shares, generating $9,540 in total proceeds. Upon buying the shares at $23.85, the President now owns 460,777 shares.
Before that, Denton John Russel bought 7,500 shares. Caris Life Sciences Inc shares valued at $157,500 were divested by the insider at a price of $21.00 per share. As a result of the transaction, Denton John Russel now holds 123,591 shares, worth roughly $3.11 million.
Wolfe Research initiated its Caris Life Sciences Inc [CAI] rating to an Outperform in a research note published on July 14, 2025; the price target was $32. A number of analysts have revised their coverage, including TD Cowen’s analysts, who began to cover the stock in mid July with a ‘”a Buy”‘ rating. JP Morgan began covering CAI with “an Overweight” recommendation on July 14, 2025. Guggenheim started covering the stock on July 14, 2025. It rated CAI as “a Buy”.
Price Performance Review of CAI
On Tuesday, Caris Life Sciences Inc [NASDAQ:CAI] saw its stock jump 1.45% to $25.16. Over the last five days, the stock has lost -19.31%. Nevertheless, the stocks have fallen -10.14% over the past one year.
Levels Of Support And Resistance For CAI Stock
The 24-hour chart illustrates a support level at 24.37, which if violated will result in even more drops to 23.58. On the upside, there is a resistance level at 25.78. A further resistance level may holdings at 26.40.
How much short interest is there in Caris Life Sciences Inc?
A steep rise in short interest was recorded in Caris Life Sciences Inc stocks on 2025-10-31, growing by 0.7 million shares to a total of 4.19 million shares. Yahoo Finance data shows the prior-month short interest on 2025-09-30 was 3.49 million shares. There was a rise of 16.78%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on July 14, 2025 when Evercore ISI began covering the stock and recommended ‘”an Outperform”‘ rating along with a $33 price target.
